Latest Investment News

Osteopore Limited has successfully raised the entire $5 million from the first tranche of its $20 million convertible notes issuance, securing funds to support ongoing operations and future growth.

Flagship Investments reported a challenging half-year with a 9.8% portfolio decline and a comprehensive loss of $6.4 million, yet maintained its commitment to dividends with a 5.1 cent fully franked interim payout.

Apiam Animal Health has secured court approval for its corporate scheme, paving the way for a fully franked special dividend payment next month.

Brisbane Broncos Limited projects a significant profit increase for 2025, driven by premiership wins in both their NRL and NRLW teams and boosted commercial revenues.

Iris Cairns Property Trust has confirmed new funding arrangements and plans to extend its takeover offer period for Reef Casino Trust, navigating regulatory hurdles and reassuring investors of its financial backing.

Bridge SaaS Limited has issued a correction to its Appendix 4C quarterly cash flow report, clarifying previously omitted financing facilities without affecting its cash position or operating results.

The Supreme Court of New South Wales has approved the scheme of arrangement for Adamantem Capital Fund II’s acquisition of Apiam Animal Health, marking a pivotal step toward the deal’s completion and the suspension of Apiam shares on the ASX.

Cannindah Resources has announced a two-tranche placement raising approximately $15 million and a concurrent Share Purchase Plan offering eligible shareholders the chance to invest up to $30,000 at a discounted price. The funds will support drilling and exploration at the Mt Cannindah Copper-Gold Project.

WAM Active Limited has launched a $51.4 million pro-rata entitlement offer at a 7.8% discount to the recent share price, alongside a $19.3 million institutional placement to meet strong investor demand. The capital raising aims to bolster the company’s proven Australian equity investment strategy while offering shareholders fully franked dividends on new shares.

Anson Resources has intersected lithium-rich brines at the Mt Fuel-Skyline Geyser well in Utah, advancing plans to upgrade its JORC resource at the Green River Lithium Project.

Terragen Holdings has raised A$7 million through a strategic equity raising to fund scientific research and accelerate global commercialisation, while appointing Dr Michele Allan AO as its new Chair.

Neuren Pharmaceuticals has dosed the first patient in its groundbreaking Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome, a rare genetic disorder with no approved therapies. The trial marks a significant step forward for the PMS community and rare disease drug development.